The Ripple Effect: Investing in Life Sciences

Investing in health and science research isn’t just about curing diseases. It has huge impacts across society, from creating jobs to driving economic growth to boosting national competitiveness. Study shows that every $ invested in the life sciences industry generates $3 in GDP globally, whereas every job created in the life sciences industry generates five in the global economy. Life sciences are one of the most powerful engines of prosperity, yet many governments still underestimate their economic return.
In this episode of The Ripple Effect: Investing in Life Sciences, host Dan Riskin speaks with Patrick Horber, President of Novartis International, and David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare at Lazard. Together, they break down the outsized economic impact of life science innovation, from trillions in US bioscience output to China’s meteoric rise as a global R&D hub. 
The conversation delves into the ways governments can support innovation with not just money, but through policy and regulation; plus, some of the best ways that countries can help the sector secure investment, talent, and long-term growth.
This limited series, produced by GZERO’s Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment.
 
Host: Dan Riskin
Guests: Patrick Horber, David Gluckman
 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What if the next virus isn’t natural, but deliberately engineered and used as a weapon? As geopolitical tensions rise and biological threats become more complex, health security and life sciences are emerging as critical pillars of national defense.
In the premiere episode of “The Ripple Effect: Investing in Life Sciences”, host Dan Riskin is joined by two leading voices at the intersection of biotechnology and defense, Dawn Meyerriecks, former CIA Deputy Director for Science and Technology and current member of the National Security Commission on Emerging Biotechnology, and Jason Kelly, co-founder and CEO of Ginkgo Bioworks. Together, they explore the dual-use nature of biotechnology and the urgent need for international oversight, genetic attribution standards, and robust viral surveillance. From pandemic preparedness and fragile supply chains to AI-driven lab automation and airport biosurveillance, their conversation highlights how life science innovation strengthens national resilience and strategic defense.
This timely conversation follows the June 25th, 2025 Hague Summit Declaration, where NATO allies pledged to invest 5% of GDP in defense by 2035—including up to 1.5% on resilience and innovation to safeguard critical infrastructure, civil preparedness, networks, and the defense industrial base. This limited series, produced by GZERO’s Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment.
 
Host: Dan Riskin
Guests: Jason Kelly, Dawn Meyerriecks

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.